197 related articles for article (PubMed ID: 35511917)
1. Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data.
Ton TGN; Pal N; Trinh H; Mahrus S; Bretscher MT; Machado RJM; Sadetsky N; Chaudhary N; Lu MW; Riely GJ
Clin Cancer Res; 2022 Jul; 28(13):2844-2853. PubMed ID: 35511917
[TBL] [Abstract][Full Text] [Related]
2. Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real-World Data.
Mhatre SK; Machado RJM; Ton TGN; Trinh H; Mazieres J; Rittmeyer A; Bretscher MT
Clin Pharmacol Ther; 2023 Dec; 114(6):1313-1322. PubMed ID: 37696652
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer.
Struebing A; McKibbon C; Ruan H; Mackay E; Dennis N; Velummailum R; He P; Tanaka Y; Xiong Y; Springford A; Rosenlund M
J Comp Eff Res; 2024 May; 13(5):e230175. PubMed ID: 38573331
[No Abstract] [Full Text] [Related]
5. Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data.
Tan K; Bryan J; Segal B; Bellomo L; Nussbaum N; Tucker M; Torres AZ; Bennette C; Capra W; Curtis M; Miksad RA
Clin Pharmacol Ther; 2022 Jan; 111(1):168-178. PubMed ID: 34197637
[TBL] [Abstract][Full Text] [Related]
6. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
Blumenthal GM; Karuri SW; Zhang H; Zhang L; Khozin S; Kazandjian D; Tang S; Sridhara R; Keegan P; Pazdur R
J Clin Oncol; 2015 Mar; 33(9):1008-14. PubMed ID: 25667291
[TBL] [Abstract][Full Text] [Related]
7. Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis.
Goring S; Varol N; Waser N; Popoff E; Lozano-Ortega G; Lee A; Yuan Y; Eccles L; Tran P; Penrod JR
Lung Cancer; 2022 Aug; 170():122-132. PubMed ID: 35767923
[TBL] [Abstract][Full Text] [Related]
8. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
10. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data.
Moran M; Nickens D; Adcock K; Bennetts M; Desscan A; Charnley N; Fife K
Target Oncol; 2019 Aug; 14(4):405-416. PubMed ID: 31301015
[TBL] [Abstract][Full Text] [Related]
12. Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data.
Taniguchi Y; Okamoto H; Shimokawa T; Sasaki T; Seto T; Niho S; Ohe Y; Saigusa Y
BMC Pulm Med; 2022 Jan; 22(1):31. PubMed ID: 35000608
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis.
Li DN; Lu WQ; Yang BW; Zhang LY; Jin B; Wang S; Che XF; Li C; Liu YP; Qu XJ
Front Immunol; 2021; 12():666909. PubMed ID: 34149702
[TBL] [Abstract][Full Text] [Related]
14. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.
Blumenthal GM; Zhang L; Zhang H; Kazandjian D; Khozin S; Tang S; Goldberg K; Sridhara R; Keegan P; Pazdur R
JAMA Oncol; 2017 Aug; 3(8):e171029. PubMed ID: 28617920
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials.
Zhao Y; Wang H; Shi Y; Cai S; Wu T; Yan G; Cheng S; Cui K; Xi Y; Qi X; Zhang J; Ma W
Oncotarget; 2017 Jan; 8(4):7014-7024. PubMed ID: 27690345
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
[TBL] [Abstract][Full Text] [Related]
18. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
19. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.
Wilkinson S; Gupta A; Scheuer N; Mackay E; Arora P; Thorlund K; Wasiak R; Ray J; Ramagopalan S; Subbiah V
JAMA Netw Open; 2021 Oct; 4(10):e2126306. PubMed ID: 34618040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
